Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications

Shan Ge,Yuwei Zhao,Jun Liang,Zhongning He,Kai Li,Guanghui Zhang,Baojin Hua,Honggang Zheng,Qiujun Guo,Runzhi Qi,Zhan Shi
DOI: https://doi.org/10.1186/s12935-024-03211-w
IF: 6.429
2024-03-14
Cancer Cell International
Abstract:Immune microenvironment and immunotherapy have become the focus and frontier of tumor research, and the immune checkpoint inhibitors has provided novel strategies for tumor treatment. Malignant pleural effusion (MPE) is a common end-stage manifestation of lung cancer, malignant pleural mesothelioma and other thoracic malignancies, which is invasive and often accompanied by poor prognosis, affecting the quality of life of affected patients. Currently, clinical therapy for MPE is limited to pleural puncture, pleural fixation, catheter drainage, and other palliative therapies. Immunization is a new direction for rehabilitation and treatment of MPE. The effusion caused by cancer cells establishes its own immune microenvironment during its formation. Immune cells, cytokines, signal pathways of microenvironment affect the MPE progress and prognosis of patients. The interaction between them have been proved. The relevant studies were obtained through a systematic search of PubMed database according to keywords search method. Then through screening and sorting and reading full-text, 300 literatures were screened out. Exclude irrelevant and poor quality articles, 238 literatures were cited in the references. In this study, the mechanism of immune microenvironment affecting malignant pleural effusion was discussed from the perspectives of adaptive immune cells, innate immune cells, cytokines and molecular targets. Meanwhile, this study focused on the clinical value of microenvironmental components in the immunotherapy and prognosis of malignant pleural effusion.
oncology
What problem does this paper attempt to address?
The paper primarily explores the immune microenvironment of Malignant Pleural Effusion (MPE) and its impact on immunotherapy and prognosis. MPE is a common terminal manifestation of advanced lung cancer, malignant pleural mesothelioma, and other thoracic malignancies, severely affecting patients' quality of life and survival time. Currently, clinical treatments for MPE mainly include palliative therapies such as thoracentesis, pleurodesis, and catheter drainage, but their effectiveness is limited. Therefore, finding new treatment methods to extend patients' survival and improve their quality of life is crucial. The paper points out that the immune microenvironment plays an important role in MPE, and immune checkpoint inhibitors provide new strategies for tumor treatment. Tumor cells in MPE establish their own immune microenvironment during formation, where immune cells, cytokines, and signaling pathways interact, influencing the development of MPE and patients' prognosis. The study systematically retrieved relevant literature from the PubMed database, screened 300 articles, and ultimately cited 238 articles for discussion. Specifically, the paper discusses how the immune microenvironment affects MPE from multiple perspectives, including adaptive immune cells (such as T lymphocyte subsets), innate immune cells, cytokines, and molecular targets. Additionally, the study focuses on the clinical value of microenvironment components in MPE immunotherapy and prognosis. Overall, this paper aims to reveal the mechanisms of the immune microenvironment in MPE and explore its potential applications in immunotherapy.